Moreover, the 36-month beta value for ADVM is 0.93. Analysts have varying opinions on the stock, with 6 analysts rating it as a “buy,” 1 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for ADVM is 11.64M and currently, short sellers hold a 13.79% of that float. On November 20, 2024, ADVM’s average trading volume was 189.89K shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
ADVM) stock’s latest price update
The stock price of Adverum Biotechnologies Inc (NASDAQ: ADVM) has dropped by -8.76 compared to previous close of 6.85. Despite this, the company has seen a fall of -20.79% in its stock price over the last five trading days. seekingalpha.com reported 2024-11-18 that Adverum Biotechnologies, Inc. achieved positive results from both the LUNA and OPTIC studies, using Ixo-vec for the treatment of patients with wet age-related macular degeneration. The phase 3 ARTEMIS study, using Ixo-vec in combination with prophylactic regimens for the treatment of patients with wet age-related macular degeneration, expected to begin 1st half of 2025. The global age-related macular degeneration market is expected to reach $19.53 billion by 2032; About 10% of all AMD patients have wet age-related macular degeneration.
ADVM’s Market Performance
Adverum Biotechnologies Inc (ADVM) has seen a -20.79% fall in stock performance for the week, with a -24.33% decline in the past month and a -13.07% plunge in the past quarter. The volatility ratio for the week is 8.98%, and the volatility levels for the past 30 days are at 5.74% for ADVM. The simple moving average for the last 20 days is -17.74% for ADVM’s stock, with a simple moving average of -38.11% for the last 200 days.
Analysts’ Opinion of ADVM
Many brokerage firms have already submitted their reports for ADVM stocks, with Oppenheimer repeating the rating for ADVM by listing it as a “Outperform.” The predicted price for ADVM in the upcoming period, according to Oppenheimer is $25 based on the research report published on June 25, 2024 of the current year 2024.
H.C. Wainwright, on the other hand, stated in their research note that they expect to see ADVM reach a price target of $30. The rating they have provided for ADVM stocks is “Buy” according to the report published on April 30th, 2024.
Truist gave a rating of “Buy” to ADVM, setting the target price at $4 in the report published on July 07th of the previous year.
ADVM Trading at -16.27% from the 50-Day Moving Average
After a stumble in the market that brought ADVM to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -78.96% of loss for the given period.
Volatility was left at 5.74%, however, over the last 30 days, the volatility rate increased by 8.98%, as shares sank -23.22% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -12.95% lower at present.
During the last 5 trading sessions, ADVM fell by -20.79%, which changed the moving average for the period of 200-days by -67.28% in comparison to the 20-day moving average, which settled at $7.60. In addition, Adverum Biotechnologies Inc saw -16.98% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ADVM starting from Leonard Braden Michael, who purchase 85,800 shares at the price of $7.15 back on Jul 30 ’24. After this action, Leonard Braden Michael now owns 2,268,064 shares of Adverum Biotechnologies Inc, valued at $613,470 using the latest closing price.
Leonard Braden Michael, the 10% Owner of Adverum Biotechnologies Inc, purchase 135,546 shares at $7.75 during a trade that took place back on Jul 17 ’24, which means that Leonard Braden Michael is holding 2,101,546 shares at $1,049,926 based on the most recent closing price.
Stock Fundamentals for ADVM
Current profitability levels for the company are sitting at:
- 43.81 for the present operating margin
- 2.48 for the gross margin
The net margin for Adverum Biotechnologies Inc stands at 36.2. The total capital return value is set at -0.55. Equity return is now at value -76.26, with -43.66 for asset returns.
Based on Adverum Biotechnologies Inc (ADVM), the company’s capital structure generated 0.07 points at debt to capital in total, while cash flow to debt ratio is standing at -8.03. The debt to equity ratio resting at 0.07. The interest coverage ratio of the stock is -94.92.
Currently, EBITDA for the company is -112.6 million with net debt to EBITDA at 0.2. When we switch over and look at the enterprise to sales, we see a ratio of -42.47. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.82.
Conclusion
To wrap up, the performance of Adverum Biotechnologies Inc (ADVM) has been bad in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
